Pfizer Reports Positive Topline Phase 3 Results For HYMPAVZI In Hemophilia A or B With Inhibitors

Pfizer Inc. (NYSE:PFE) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Pfizer Inc. (NYSE:PFE) reported positive topline results from its Phase 3 BASIS study, which evaluated HYMPAVZI™ (marstacimab) in patients with hemophilia A or B with inhibitors.

The annualized bleeding rate was reduced by 93% with once-weekly subcutaneous medication as opposed to on-demand intravenous treatment (1.39 vs. 19.78; p < 0.0001). Furthermore, HYMPAVZI was superior in all secondary endpoints linked to bleeding and was usually well-tolerated; no thromboembolic events or fatalities were observed.

HYMPAVZI was investigated in 48 patients over 12 months, with a focus on a high-need population: 20% of hemophilia A and 3% of hemophilia B patients develop inhibitors that negate traditional factor replacement therapy. Pfizer Inc. (NYSE:PFE) developed the treatment, which functions by blocking the tissue factor pathway inhibitor instead of substituting FVIII or FIX. HYMPAVZI, which is administered using a pre-filled pen, provides patients with few other options with a straightforward preventative approach. Pfizer Inc. (NYSE:PFE) will begin regulatory filings after conducting a thorough data review. It is among the Best Weight Loss Stocks.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.